Dublin, March 07, 2018 -- The "Global Personalized Medicine Partnering 2012-2018: Deal trends, players, financials and forecasts" report has been added to ResearchAndMarkets.com's offering.
The Global Personalized Medicine Partnering 2012-2018 report provides comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies.
This report provides details of the latest Personalized Medicine agreements announced in the life sciences since 2012.
The report takes the reader through a comprehensive review Personalized Medicine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Personalized Medicine partnering deals.
The report presents financial deal term values for Personalized Medicine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the Personalized Medicine partnering field; both the leading deal values and most active Personalized Medicine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 1,370 online deal records of actual Personalized Medicine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
Key benefits
- In-depth understanding of Personalized Medicine deal trends since 2012
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of Personalized Medicine agreements with numerous real life case studies
- Detailed access to actual Personalized Medicine contracts entered into by leading biopharma companies
- Identify most active Personalized Medicine dealmakers since 2012
- Insight into terms included in a Personalized Medicine partnering agreement, with real world examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope
Personalized Medicine Partnering Terms and Agreements includes:
- Trends in Personalized Medicine dealmaking in the biopharma industry since 2012
- Analysis of Personalized Medicine deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life Personalized Medicine deals
- Access to Personalized Medicine contract documents
- Leading Personalized Medicine deals by value since 2012
- Most active Personalized Medicine dealmakers since 2012
Available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
- Technology type
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Personalized Medicine dealmaking
2.1. Introduction
2.2. Personalized Medicine partnering over the years
2.3. Most active Personalized Medicine dealmakers
2.4. Personalized Medicine partnering by deal type
2.5. Personalized Medicine partnering by therapy area
2.6. Deal terms for Personalized Medicine partnering
Chapter 3 - Leading Personalized Medicine deals
3.1. Introduction
3.2. Top Personalized Medicine deals by value
Chapter 4 - Most active Personalized Medicine dealmakers
4.1. Introduction
4.2. Most active Personalized Medicine dealmakers
4.3. Most active Personalized Medicine partnering company profiles
Chapter 5 - Personalized Medicine contracts dealmaking directory
5.1. Introduction
5.2. Personalized Medicine contracts dealmaking directory
Chapter 6 - Personalized Medicine dealmaking by technology type
Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
For more information about this report visit https://www.researchandmarkets.com/research/sfzcd7/global?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Genomics


Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 



